FYI re Medivir
I heard that JNJ's Cowen session that listed TMC435 as one out of six important growth drivers in pipeline.
Also, didnt notice this but during Q4'11/FY'11 call they had this in the Q&A
_______________
Michael N. Weinstein - JP Morgan Chase & Co, Research Division
Okay. Bill, let me ask you about 2 pipeline areas. A big driver in 2012 is going to be INCIVO, telaprevir, for the company. The landscape for HCV has changed a lot in the last 6 to 12 months. Obviously, there's a lot of competition for assets right now. Can you just talk about, given how important that's going to become to the company as a revenue contributor in 2012 and '13, how you're viewing the competitive positioning of J&J going forward in that area because it becomes an important area for you? And then the second one I'd like to comment on is on Bapi. We're going to get the readout on 2 of the North American trials in 2012. You mentioned in your slides, potential filing in '12, '13. Is that your expectation in how you are positioning? How do you want us to think about potential for the Bapi data in '12, '13? Should we be assuming that this is going to file in '12, '13 on the data that you're going to be generating?
William C. Weldon
Yes, the Bapi one I'll answer first, Mike. Yes, we expect that we'll have the data analyzed and we'll be filing obviously on a positive outcome by the end of the year would be our expectation on Bapi. And then when you go to INCIVO in the hepatitis C, that's an area where there's a whole lot of interest in various areas. There's a Pharmasset acquisition that's taking place and others. We feel really good about where we are with INCIVO.
We feel very good about 435, which will be a complementary product. And we feel that we'll be able to get out there and work in the hepatitis C area with those compounds. And then the other ones that are there, they're still very early in development there. I guess they're going into IIb right now, and we're going to wait and see what exactly happens there. But we think that we're very well positioned for the hepatitis C with the 2 compounds we have.
Michael N. Weinstein - JP Morgan Chase & Co, Research Division
So in short, you feel you have in-house right now what you need to be competitive in what will be the second wave of new compounds that are coming out?
William C. Weldon
We feel we're in a good position and there may be opportunities to look to the future and see how we could work with others if those nukes become better products.
Market Data 
Markets 
AI
